Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

HEART FAILURE

ELECTROPHYSIOLOGY

CLINICAL

155 - CCC-ACQ WORKSHOP ON ADVANCES IN HEART FAILURE THERAPIES

Thursday, October 24, 2024
3:15 PM – 4:15 PM PT
Room: 212-213
Workshop Description: This workshop is intended to be presented in French, as part of the partnership with CCC and ACQ.
This workshop will fulfill the learning needs of those seeking a comprehensive overview of heart failure therapies. Clinical scenarios like those addressed in this workshop are a frequent challenge to all involved in the clinical management of heart failure patients. This workshop will provide participants with a comprehensive, and practical approach to patient selection and referral for advanced medical treatment, valvular and atrial fibrillation interventional therapies. An appropriate description of the technical aspects of interest to the general cardiologist, appropriate follow-up and expected outcomes after such procedures.
The ACQ CME committee planned this workshop. Members of this committee include community and academic cardiologists, interventional cardiologist and cardiology resident from diverse practices and experiences across Quebec. The ACQ CME has developed an objective and balanced representation of the topic of " Atelier conjoint ACQ-CCC: les avancées dans le traitement de l'insuffisance cardiaque"
that is completely free of third-party influence and/or support. Selected speakers from across Quebec are representative of diversity in gender, generation and practice

Interactive and Engagement Activities Description: Each speaker will open with a case presentation relevant to the topic assigned. Each presentation will last 10 minutes and include 2 question-and-answer to promote interactive learning via audience response system. Each presentation will last 12 minutes which will allow for 36 minutes of presentations and 24 minutes of discussion.

Learning Objectives:

At the end of this session participants will be able to:
  • perceive the medical advances in the treatment of heart failure with reduced or preserved ejection fraction;
  • identify patients living with heart failure eligible for percutaneous valve repair; and
  • recognize the indications and new developments in the treatment of atrial fibrillation in patients living with heart failure.
Disclosure(s):
Samer Mansour, MD: No financial relationships to disclose
Isabelle Nault, MD: Bayer: Speaker bureau (Ongoing); Biosense Webster: speaker bureau (Ongoing); Medtronic: Speaker honoraria (Ongoing); Servier: Speaker bureau (Ongoing)
Jean-Bernard Masson, MD: No financial relationships to disclose
Christian Steinberg, MD: BMS: consultant fees & speaker honoraria (Ongoing), National Advisory Board Canada on Mavacamten (Ongoing)
François Tournoux, MD: Alnylam: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Astra Zeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bristol Myers Squibb: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Quebec Heart Failure Society: Employment (Ongoing)